Fusion Antibodies Plc (FAB.L)

3.3400 +0.0650 (+1.98%) As of 01:17PM BST. Market open.

Fusion Antibodies Plc

1 Springbank Road
Springbank Industrial Estate Dunmurry
Belfast BT17 0QL
United Kingdom
44 28 9043 2800
https://www.fusionantibodies.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 48

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Adrian Robert Kinkaid Ph.D.	CEO & Director	183.49k	N/A	1967
Dr. Richard John Buick Ph.D.	Chief Scientific Officer & Director	127k	N/A	1976
Prof. Jim Johnston	Founder	N/A	N/A	N/A
Mr. Stephen Barry Smyth	Company Secretary, Interim CFO & Director	N/A	N/A	1974
Ms. Nicola Hamilton	Operations Manager	N/A	N/A	N/A
Dr. Paul Gerard Kerr	Consultant	180.38k	N/A	1973

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, and diagnostic companies. The company has a collaboration partnership with Celonic AG. The company was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.

Corporate governance

Fusion Antibodies Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.